Tailoring FSH and LH administration to individual patients

Reproductive BioMedicine Online

Volumn 11, Issue 3, 2005, Pages 283-293

  Borini, Andrea ^a   Dal Prato, Luca ^a  

^a Tecnobios Procreazione   (Italy)

Author keywords

Body mass index; FSH; Individual dose; LH; Ovarian response; Ovarian stimulation

Indexed keywords

BUSERELIN; ESTRADIOL; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

AGE; ARTICLE; BODY MASS; CHILDBIRTH; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; NIDATION; OBESITY; OOCYTE; OVARY DISEASE; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; OVULATION INDUCTION; PREGNANCY;

EID: 24644512802     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60835-8     Document Type: Article

References (78)

1. Al-Inany HG, Aboulghar M, Mansour R et al. 2005 Optimizing GnRH antagonist administration: meta-analysis of fixed vs flexible protocol. Reproductive BioMedicine Online 10, 567-570.
2. Balasch J, Vidal E, Penarrubia J et al. 2001 Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Human Reproduction 16, 1636-1643.
3. Bassett RM, Driebergen R 2005 Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reproductive BioMedicine Online 10, 169-177.
4. Ben-Amor AF 2000 The effect of luteinizing hormone administered during the late follicular phase in normo-ovulatory women undergoing in-vitro fertilization. Human Reproduction 15 (suppl. 1), 46.
5. Bergh C, Howles CM, Borg K et al. 1997 Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques. Human Reproduction 12, 2133-2139.
6. Bourgain C, Ubaldi F, Tavaniotou A et al. 2002 Endometrial hormone receptors and proliferation index in the periovulatory phase of stimulated embryo transfer cycles in comparison with natural cycles and relation to clinical pregnancy outcome. Fertility and Sterility 78, 237-244.
7. Cabrera RA, Stadtmauer L, Mayer JF et al. 2005 Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone. Fertility and Sterility 83, 42-48.
8. Caglar GS, Asimakopoulos B, Nikolettos N et al. 2005 Recombinant luteinizing hormone in ovarian stimulation. Reproductive BioMedicine Online 10, 774-785.
9. Cahill DJ, Prosser CJ, Wardle PG et al. 1994 Relative influence of serum follicle stimulating hormone, age and other factors on ovarian response to gonadotrophin stimulation. British Journal of Obstetrics and Gynaecology 101, 999-1002.
10. Cédrin-Durnerin I, Grange-Dujardin D, Laffy A et al. 2004 Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Human Reproduction 19, 1979-1984.
11. Chang MY, Chiang CH, Hsieh TT et al. 1998 Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertility and Sterility 69, 505-510.
12. Chappel SC, Howles C 1991 Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Human Reproduction 6, 1206-1212.
13. Dal Prato L, Borini A 2005 Use of antagonists in ovarian stimulation protocols. Reproductive BioMedicine Online 10, 330-338.
14. Dal Prato L, Borini A, Coticchio G et al. 2004 Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study. Human Reproduction 19, 2200-2205.
15. Dal Prato L, Borini A, Trevisi MR et al. 2001 Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study. Human Reproduction 16, 1409-1414.
16. De Placido G, Alviggi C, Perino A et al. 2005 Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction 20, 390-396.
17. Dobbs KE, Dumesic DA, Dumesic JA et al. 1994 Differences in serum follicle-stimulating hormone uptake after intramuscular and subcutaneous human menopausal gonadotropin injection. Fertility and Sterility 62, 978-983.
18. El-Nemr A, Al-Shawaf T, Sabatini L et al. 1998 Effect of smoking on ovarian reserve and ovarian stimulation in in-vitro fertilization and embryo transfer. Human Reproduction 13, 2192-2198.
19. Engmann L, Sladkevicius P, Agrawal R et al. 1999 Value of ovarian stromal blood flow velocity measurement after pituitary suppression in the prediction of ovarian responsiveness and outcome of in vitro fertilization treatment. Fertility and Sterility 71, 22-29.
20. European Recombinant Human LH Study Group 1998 Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group. Journal of Clinical Endocrinology and Metabolism 83, 1507-1514.
21. Fedorcsak P, Dale PO, Storeng R et al. 2004 Impact of overweight and underweight on assisted reproduction treatment. Human Reproduction 19, 2523-2528.
22. Feldberg D, Farhi J, Ashkenazi J et al. 1994 Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertility and Sterility 62, 343-346.
23. Ferraretti AP, Gianaroli L, Magli MC et al. 2004 Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertility and Sterility 82, 1521-1526.
24. Fevold HL 1941 Synergism of follicle stimulating and luteinizing hormone. Journal of Assisted Reproduction and Genetics 28, 33-36.
25. Filicori M, Cognigni GE, Taraborrelli S et al. 2001 Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. Journal of Clinical Endocrinology and Metabolism 86, 337-343.
26. Fleming R, Rehka P, Deshpande N et al. 2000 Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Human Reproduction 15, 1440-1445.
27. Fleming R, Lloyd F, Herbert M et al. 1998 Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Human Reproduction 13, 1788-1792.
28. Fleming R, Chung CC, Yates RW et al. 1996 Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Human Reproduction 11, 1854-1858.
29. Ganirelix Dose-Finding Study Group 1998 A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Human Reproduction 13, 3023-3031.
30. Gerli S, Casini ML, Unfer V et al. 2004 Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost-effectiveness. Reproductive BioMedicine Online 9, 494-499.
31. Harrison RF, Jacob S, Spillane H et al. 2001 A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility 75, 23-31.
32. Hazout A, Bouchard P, Seifer DB et al. 2004 Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility and Sterility 82, 1323-1329.
33. Hendriks DJ, Mol BW, Bancsi LF et al. 2005 Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertility and Sterility 83, 291-301.
34. Hugues JN, Barlow DH, Rosenwaks Z et al. 2003 Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method for calibrating the therapeutic preparation. Reproductive BioMedicine Online 6, 185-190.
35. Humaidan P, Bungum M, Bungum L et al. 2004 Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reproductive BioMedicine Online 8, 635-643.
36. Humaidan P, Bungum L, Bungum M et al. 2002 Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Human Reproduction 17, 2016-2021.
37. Janssens RM, Lambalk CB, Vermeiden JP et al. 2000 Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study [In Process Citation]. Human Reproduction 15, 2333-2340.
38. Jones HW Jr, Out HJ, Hoomans EH et al. 1997 Cryopreservation: the practicalities of evaluation. Human Reproduction 12, 1522-1524.
39. Klinkert ER, Broekmans FJ, Looman CW et al. 2005 Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction 20, 611-615.
40. Kol S, Muchtar M 2005 Recombinant gonadotrophin-based, ovarian hyperstimulation syndrome-free stimulation of the high responder: suggested protocol for further research. Reproductive BioMedicine Online 10, 575-577.
41. Kolibianakis EM, Tarlatzis BC, Devroey P 2005 GnRH antagonists in IVF. Reproductive BioMedicine Online 10, 705-712.
42. Kolibianakis EM, Zikopoulos K, Schiettecatte J et al. 2004 Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Human Reproduction 19, 2490-2496.
43. Lashen H, Ledger W, Bernal AL et al. 1999 Extremes of body mass do not adversely affect the outcome of superovulation and in-vitro fertilization. Human Reproduction 14, 712-715.
44. Lass A, Skull J, McVeigh E et al. 1997 Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotrophin for in-vitro fertilization can predict poor response. Human Reproduction 12, 294-297.
45. Latin-American Puregon IVF Study Group 2001 A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization. Fertility and Sterility 76, 950-956.
46. Levy DP, Navarro JM, Schattman GL et al. 2000 The role of LH in ovarian stimulation: exogenous LH: let's design the future. Human Reproduction 15, 2258-2265.
47. Lewis CG, Warnes GM, Wang XJ et al. 1990 Failure of body mass index or body weight to influence markedly the response to ovarian hyperstimulation in normal cycling women. Fertility and Sterility 53, 1097-1099.
48. Lisi F, Rinaldi L, Fishel S et al. 2002 Use of recombinant LH in a group of unselected IVF patients. Reproductive BioMedicine Online 5, 104-108.
49. Lisi F, Rinaldi L, Fishel S et al. 2001 Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study. Reproductive BioMedicine Online 3, 190-194.
50. Loumaye E, Engrand P, Shoham Z et al. 2003 Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Human Reproduction 18, 314-322.
51. Loumaye E, Engrand P, Howles CM et al. 1997 Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertility and Sterility 67, 889-899.
52. Loumaye E, Vankrieken L, Depreester S et al. 1989 Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development. Fertility and Sterility 51, 105-111.
53. MacDougall MJ, Tan SL, Balen A et al. 1993 A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Human Reproduction 8, 233-237.
54. Marrs R, Meldrum D, Muasher S et al. 2004 Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive BioMedicine Online 8, 175-182.
55. Ng EH, Tang OS, Ho PC 2000 The significance of the number of antral follicles prior to stimulation in predicting ovarian responses in an IVF programme. Human Reproduction 15, 1937-1942.
56. Out HJ, Rutherford A, Fleming R et al. 2004 A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction 19, 90-95.
57. Out HJ, David I, Ron-El R et al. 2001 A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Human Reproduction 16, 1104-1109.
58. Out HJ, Braat DD, Lintsen BM et al. 2000 Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Human Reproduction 15, 29-35.
59. Out HJ, Lindenberg S, Mikkelsen AL et al. 1999 A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Human Reproduction 14, 622-627.
60. Out HJ, Mannaerts BM, Driessen SG et al. 1995 A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Human Reproduction 10, 2534-2540.
61. Penzias AS 2004 Improving results with assisted reproductive technologies: individualized patient-tailored strategies for ovulation induction. Reproductive BioMedicine Online 9, 43-46.
62. Popovic-Todorovic B, Loft A, Bredkjaeer HE et al. 2003a A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction 18, 2275-2282.
63. Popovic-Todorovic B, Loft A, Lindhard A et al. 2003b A prospective study of predictive factors of ovarian response in 'standard' IVF/ ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Human Reproduction 18, 781-787.
64. Seifer DB, Lambert-Messerlian G, Hogan JW et al. 1997 Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertility and Sterility 67, 110-114.
65. Sharif K, Elgendy M, Lashen H et al. 1998 Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome. British Journal of Obstetrics and Gynaecology 105, 107-112.
66. Shoham Z 2002 The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertility and Sterility 77, 1170-1177.
67. Steinkampf MT, Hammond KR, Nichols JE et al. 2003 Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration. Fertility and Sterility 80, 99-102.
68. Syrop CH, Dawson JD, Husman KJ et al. 1999 Ovarian volume may predict assisted reproductive outcomes better than follicle stimulating hormone concentration on day 3. Human Reproduction 14, 1752-1756.
69. Tesarik J 2003 Luteining hormone affects uterine receptivity independently of ovarian function. Reproductive BioMedicine Online 7, 59-64.
70. Tesarik J, Mendoza C 2002 Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Human Reproduction 17, 3129-3137.
71. Toner JP, Philput CB, Jones GS et al. 1991 Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertility and Sterility 55, 784-791.
72. Ubaldi FM, Rienzi L, Ferrero S et al. 2005 Management of poor responders in IVF. Reproductive BioMedicine Online 10, 235-246.
73. Wang JX, Davies MJ, Norman RJ 2002 Obesity increases the risk of spontaneous abortion during infertility treatment. Obesity Research 10, 551-554.
74. Westergaard LG, Erb K, Laursen SB et al. 2001 Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertility and Sterility 76, 543-549.
75. Westergaard LG, Laursen SB, Andersen CY 2000 Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Human Reproduction 15, 1003-1008.
76. Wittemer C, Ohl J, Bailly M et al. 2000 Does body mass index of infertile women have an impact on IVF procedure and outcome? Journal of Assisted Reproduction and Genetics 17, 547-552.
77. Yong PY, Brett S, Baird DT et al. 2003 A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility 79, 308-315.
78. Zullo F, Di Carlo C, Pellicano M et al. 1996 Superovulation with urinary human follicle-stimulating hormone: correlations with body mass index and body fat distribution. Gynecological Endocrinology 10, 17-21.